Product Overview
Retatrutide is a synthetic research peptide supplied by PeptaCo for qualified laboratory applications. It is designed to interact with multiple metabolic receptor pathways — GLP-1, GIP, and glucagon receptors — making it a research tool for studying multi-pathway metabolic signaling and receptor cross-talk.
Key Product Details
- Product Name: Retatrutide
- Specification: As listed per catalog variant
- Product Form: Lyophilized powder
- Category: Metabolic Research Peptides — Triple Receptor Agonist
- Receptor Targets: GLP-1 receptor, GIP receptor, Glucagon receptor
Chemical Identity
Retatrutide is a synthetic peptide-based research compound engineered for triple receptor engagement. The molecular design enables investigation of coordinated signaling across GLP-1, GIP, and glucagon receptor systems. Molecular Formula: C₂₃₃H₃₄₃N₅₅O₇₀. Molecular Weight: ~5198 Da. PubChem CID: 171390338.
Research Context
Retatrutide is a next-generation research compound for studying multi-pathway metabolic regulation. Its triple-agonist profile enables comparative studies of receptor cross-talk, coordinated signaling, and complex metabolic pathway interactions. PeptaCo supplies Retatrutide in multiple specifications (5mg, 10mg, 15mg, 20mg, 30mg, 60mg) to support diverse research protocols.
Storage and Handling
Store in a cool, dry place away from direct light. Follow batch-specific storage instructions provided with the certificate of analysis. Avoid repeated freeze-thaw cycles. Handle using standard laboratory practices.
Documentation and Quality
Batch-specific analytical documentation is available to qualified customers upon request. Contact PeptaCo with the product SKU and required quantity to request the current documentation package, which may include identity confirmation, purity analysis, and batch traceability records.
Important Notice
This product is supplied for qualified laboratory research and analytical applications only. It is not for human or veterinary use. Product specifications may vary by batch. Appearance, analytical results, counter-ion information, and other release specifications should be confirmed against the certificate issued for the current batch.
